Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Gafchromic films support patient care in oncology
The product is expected to be launched by Q4 FY23.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Healthcare is timely and personal – and its delivery should be too
Subscribe To Our Newsletter & Stay Updated
